# Alembic Pharmaceuticals Limited (APLLTD)

> APLLTD closed at ₹798.65 on 30 Oct 2026, trailing P/E 22.8, market cap ₹15,697 cr, latest results for the quarter ended 30 Jun 2026. Revenue, profit, ROE, debt, own P/E range and sector-peer comparison from the SEBI filing.

Alembic Pharmaceuticals Limited (NSE: APLLTD) closed at ₹798.65 on 30 Oct 2026, -14.9% over one year, against a 52-week range of ₹635.80 – ₹998.00.

In the quarter ended 30 Jun 2026 (consolidated, filed 4 Aug 2026) it reported revenue of ₹2,150 cr and net profit of ₹173 cr, a 8.1% net margin; revenue grew 25.7% and profit grew 16.2% year on year.

On four consecutive filed quarters its trailing P/E is 22.8; since 12 May 2025 its own P/E has ranged from 20.2 to 35.0 (median 25.7), and today's reading is higher than 17% of those 364 trading days.

From the balance sheet dated 31 Mar 2026: return on equity 12.2%, ROCE 16.2%, debt-to-equity 0.24, Piotroski F-score 7 of 9.

Against 66 Healthcare peers on NSE: Net margin higher than 19% of 64 sector peers; PBT margin higher than 16% of 64 sector peers; ROE higher than 42% of 64 sector peers.

## Key figures

| Figure | Value |
|---|---|
| Last close | ₹798.65 (30 Oct 2026) |
| Change 1 month / 6 months / 1 year | -6.0% / +6.3% / -14.9% |
| 52-week low – high | ₹635.80 – ₹998.00 |
| Market capitalisation | ₹15,697 cr |
| Trailing P/E | 22.8 |
| Price / book | 2.77 |
| EV / EBITDA | 14.5 |
| Earnings yield | 4.4% |
| TTM EPS | ₹35.08 |
| TTM net profit | ₹690 cr |
| Quarter revenue | ₹2,150 cr |
| Quarter net profit | ₹173 cr |
| Net margin | 8.1% |
| Revenue growth (YoY) | +25.7% |
| Profit growth (YoY) | +16.2% |
| Return on equity | 12.2% |
| ROCE | 16.2% |
| Debt / equity | 0.24 |
| Current ratio | 1.75 |
| Free cash flow | ₹348 cr |
| Piotroski F-score | 7 / 9 |
| Average daily turnover (50 days) | ₹11.1 cr |

## Questions

### What is the P/E ratio of Alembic Pharmaceuticals Limited?

Alembic Pharmaceuticals Limited's trailing P/E is 22.8, using the close of 30 Oct 2026 and earnings over the four filed quarters to 30 Jun 2026. Since 12 May 2025 its P/E has ranged 20.2–35.0.

### What were Alembic Pharmaceuticals Limited's latest quarterly results?

For the quarter ended 30 Jun 2026, Alembic Pharmaceuticals Limited reported revenue of ₹2,150 cr and net profit of ₹173 cr (consolidated), filed with the exchange on 4 Aug 2026.

### What is Alembic Pharmaceuticals Limited's ROE?

Return on equity is 12.2% based on the balance sheet dated 31 Mar 2026.

### Does Alembic Pharmaceuticals Limited have debt?

Debt-to-equity is 0.24 on the balance sheet dated 31 Mar 2026.

### What is APLLTD's 52-week high and low?

Over the last 52 weeks to 30 Oct 2026, APLLTD traded between ₹635.80 and ₹998.00.

Sector: [Healthcare](https://trinetra.trade/sectors/healthcare) · Page: https://trinetra.trade/fundamentals/APLLTD

_TRINETRA is a research and education tool. Nothing on this site is investment advice or a recommendation to buy or sell any security. Markets carry risk; do your own research and consult a SEBI-registered adviser before investing._